ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy


ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy.  This VISION-DMD study (clinicaltrials.gov NCT03439670) will enroll approximately 120 patients at ~30 sites in US, Canada, Israel, United Kingdom, Sweden, Australia, Netherlands, Belgium, and Czech Republic.

https://www.duchennexchange.org/wp-content/uploads/2018/08/reveragen-logo.jpg